196 related articles for article (PubMed ID: 29262623)
1. Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth
Chen Z; Zhao Y; Yu Y; Pang JC; Woodfield SE; Tao L; Guan S; Zhang H; Bieerkehazhi S; Shi Y; Patel R; Vasudevan SA; Yi JS; Muscal JA; Xu GT; Yang J
Oncotarget; 2017 Nov; 8(61):104090-104103. PubMed ID: 29262623
[TBL] [Abstract][Full Text] [Related]
2. Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth.
Ruan H; Luo H; Wang J; Ji X; Zhang Z; Wu J; Zhang X; Wu X
Biochim Biophys Acta; 2016 Sep; 1860(9):1961-72. PubMed ID: 27316313
[TBL] [Abstract][Full Text] [Related]
3. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
4. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
5. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
Takenobu H; Shimozato O; Nakamura T; Ochiai H; Yamaguchi Y; Ohira M; Nakagawara A; Kamijo T
Oncogene; 2011 Jan; 30(1):97-105. PubMed ID: 20818439
[TBL] [Abstract][Full Text] [Related]
6. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
8. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
9. The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation.
Peterson S; Bogenmann E
Oncogene; 2004 Jan; 23(1):213-25. PubMed ID: 14712226
[TBL] [Abstract][Full Text] [Related]
10. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
11. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
[TBL] [Abstract][Full Text] [Related]
14. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
[TBL] [Abstract][Full Text] [Related]
15. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.
Chilamakuri R; Agarwal S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205815
[TBL] [Abstract][Full Text] [Related]
16. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
17. MELK is a novel therapeutic target in high-risk neuroblastoma.
Guan S; Lu J; Zhao Y; Yu Y; Li H; Chen Z; Shi Z; Liang H; Wang M; Guo K; Chen X; Sun W; Bieerkehazhi S; Xu X; Sun S; Agarwal S; Yang J
Oncotarget; 2018 Jan; 9(2):2591-2602. PubMed ID: 29416794
[TBL] [Abstract][Full Text] [Related]
18. RET receptor expression and interaction with TRK receptors in neuroblastomas.
Tetri LH; Kolla V; Golden RL; Iyer R; Croucher JL; Choi JH; Macfarland SP; Naraparaju K; Guan P; Nguyen F; Gaonkar KS; Raman P; Brodeur GM
Oncol Rep; 2020 Jul; 44(1):263-272. PubMed ID: 32319659
[TBL] [Abstract][Full Text] [Related]
19. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
20. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
